Selux Diagnostics
Selux Diagnostics, Inc. designs automated software solutions for AST results and susceptibility testing in the US.
Founded
2014Selux Diagnostics, Inc. designs automated software solutions for AST results and susceptibility testing in the US.
Founded with the mission to revolutionize clinical diagnostics, Selux Diagnostics, Inc. focuses on developing advanced software solutions for automated antimicrobial susceptibility testing (AST). Their core vision is to enhance the speed and accuracy of susceptibility testing to combat antibiotic resistance effectively. The company's flagship product, the Selux NGP System, provides rapid AST results and same-shift susceptibility testing, catering primarily to healthcare providers in the United States.
Selux Diagnostics has garnered attention through notable FDA clearance for its Selux NGP System, marking a significant milestone in rapid AST technology. The company collaborates with leading healthcare professionals and institutions to refine its offerings continually. By addressing one of the most pressing medical challenges—antibiotic resistance—Selux Diagnostics has made a substantial impact on improving patient outcomes and optimizing antibiotic use in clinical settings.
Companies similar to Selux Diagnostics include Specific Diagnostics, Accelerate Diagnostics, Acenxion Biosystems and Astek Diagnostics.
Selux Diagnostics was founded in 2014.
Selux Diagnostics' headquarters is located in Charlestown, MA, US.
Selux Diagnostics' most recent funding round was for $8M (USD) in July 2022.
As of Jul 12, 2022, Selux Diagnostics has disclosed funding of $172.5M (USD). Undisclosed round amounts are excluded.
Selux Diagnostics has 70 employees as of Feb 5, 2024.
astekdx.com
